Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 22, 2017
What is the competitive landscape for HOFFMANN LA ROCHE, and when can generic versions of HOFFMANN LA ROCHE drugs launch?
HOFFMANN LA ROCHE has fourteen approved drugs.| Patents: | 14 |
| Tradenames: | 12 |
| Ingredients: | 11 |
| NDAs: | 14 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
valganciclovir hydrochloride | For Oral Solution | 50 mg/mL | VALCYTE | 3/21/2011 |
capecitabine | Tablets | 150 mg and 500 mg | XELODA | 11/10/2008 |
ibandronate sodium | Injection | 1 mg/mL, 3 mL Vial | BONIVA | 8/31/2007 |
ibandronate sodium | Tablets | 2.5 mg and 150 mg | BONIVA | 5/16/2007 |
valganciclovir hydrochloride | Tablets | 450 mg | VALCYTE | 12/27/2005 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,663,517 | Compositions and uses thereof | ► Subscribe | |||||||||||||||||||||||||||
| 8,889,109 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | ► Subscribe | |||||||||||||||||||||||||||
| 6,627,221 | Pharmaceutical composition containing diphosphonic acid or salt thereof | ► Subscribe | |||||||||||||||||||||||||||
| 8,415,469 | Compounds and methods for kinase modulation, and indications therefor | ► Subscribe | |||||||||||||||||||||||||||
| 7,846,941 | Compounds modulating c-kit and c-fms activity and uses therefor | ► Subscribe | |||||||||||||||||||||||||||
| 8,530,661 | Process for the manufacture of pharmaceutically active compounds | ► Subscribe | |||||||||||||||||||||||||||
| 8,329,724 | Process for the manufacture of pharmaceutically active compounds | ► Subscribe | |||||||||||||||||||||||||||
| 8,067,434 | Compounds and methods for development of Ret modulators | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taiwan | I404719 | ► Subscribe | |||||||||||||||||||||||||||
| Argentina | 054350 | ► Subscribe | |||||||||||||||||||||||||||
| Hungary | 225035 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 187344 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | I347188 | ► Subscribe | |||||||||||||||||||||||||||
| San Marino | T201500302 | ► Subscribe | |||||||||||||||||||||||||||
| Peru | 04402004 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2671470 | ► Subscribe | |||||||||||||||||||||||||||
| Argentina | 069942 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2007332640 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | Finland | ► Subscribe | |||||||||||||||||||||||||||
| 00045 | Netherlands | ► Subscribe | PRODUCT NAME: CAPECITABINE,DESGEWENST IN DE VORM VAN EEN SOLVAAT; NATL REGISTRATION NO/DATE: EU/1/00/163/001-002 20010202; FIRST REGISTRATION: CH 54657 19980610 | ||||||||||||||||||||||||||
| C0003 | France | ► Subscribe | PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920 | ||||||||||||||||||||||||||
| 90026-2 | Sweden | ► Subscribe | PRODUCT NAME: VEMURAFENIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/12/751/001 20120217 | ||||||||||||||||||||||||||
| 2012000043 | Germany | ► Subscribe | PRODUCT NAME: VEMURAFENIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 | ||||||||||||||||||||||||||
| 0120016 00059 | Estonia | ► Subscribe | PRODUCT NAME: ZELBORAF - VEMURAFENIIB;REG NO/DATE: C(2012)1180 FINAL 17.02.2012 | ||||||||||||||||||||||||||
| 00534 | Netherlands | ► Subscribe | PRODUCT NAME: VEMURAFENIB ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 | ||||||||||||||||||||||||||
| 035 | Luxembourg | ► Subscribe | 92035, EXPIRES: 20270217 | ||||||||||||||||||||||||||
| C/GB02/027 | United Kingdom | ► Subscribe | PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425 | ||||||||||||||||||||||||||
| 01C/021 | Belgium | ► Subscribe | PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,738 others who get our Drug Patent Expiration Alerts:
